Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 4,301–4,400 of 15,747
Risks posed by SARS‐CoV‐2 to North American bats during winter fieldwork
Cook, J. D., Grant, E. H. C., Coleman, J. T. H., Sleeman, J. M., & Runge, M. C. (2021) · Conservation Science and Practice · doi:10.1111/csp2.410 · Cited by 25
Manfredi, R., Bianco, F., Bucciarelli, V., Ciliberti, G., Guerra, F., Schicchi, N., Tavio, M., Berton, E., Surace, F. C., Colaneri, M., et al. (2022) · Vaccines · doi:10.3390/vaccines10020169 · Cited by 24
“In addition, the benefit-risk for COVID-19 vaccination has been already proven, showing a favorable balance for vaccination in all age and sex groups [4].”
BackgroundHendricks, G. G., Grigoryan, L., Navarro, M. J., Catanzaro, N., Hubbard, M. L., Powers, J. M., Mattocks, M. D., Treichel, C., Walls, A. C., Lee, J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu2085 · Cited by 28
Anaphylaxis After the Covid-19 Vaccine in a Patient With Cholinergic Urticaria
Park, H. J., Montgomery, J. R., & Boggs, N. A. (2021) · Military Medicine · doi:10.1093/milmed/usab138 · Cited by 23
Wei, Q., Liu, S., Huang, X., Xin, H., & Ding, J. (2022) · Biosafety and Health · doi:10.1016/j.bsheal.2022.11.002 · Cited by 24
Lipid nanoparticles deliver mRNA to the blood–brain barrier
Kuzminich, Y., Shakked, A., Calkins, R., Rudden, S., Jones, C., Doan, J., Jang, B., Echeverri, E. S., Zenhausern, R., Lian, L., et al. (2024) · Nano Research · doi:10.1007/s12274-024-6827-7 · Cited by 26
Ho, M., Zanwar, S., Buadi, F. K., Ailawadhi, S., Larsen, J. T., Bergsagel, P. L., Binder, M., Chanan-Khan, A. A., Dingli, D., Dispenzieri, A. A., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26762 · Cited by 25
Advancing Cancer Immunotherapy: The Potential of mRNA Vaccines As a Promising Therapeutic Approach
Goyal, F., Chattopadhyay, A., Navik, U., Jain, A., Reddy, P. H., Bhatti, G. K., & Bhatti, J. S. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300255 · Cited by 29
Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis
Fico, G., Isayeva, U., Prisco, M. D., Oliva, V., Solé, B., Montejo, L., Grande, I., Arbelo, N., Gómez-Ramiro, M., Pintor, L., et al. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.10.004 · Cited by 24
Raw, R. K., Rees, J. C., Kelly, C. A., Wroe, C., & Chadwick, D. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.090 · Cited by 24
“Rachael K. Raw a,⇑, Jon Rees b, Clive A. Kelly c, Caroline Wroe d, David R. Chadwick e a School of Medicine and Health, Newcastle University, Newcastle upon Tyne, UK b The School of Psychology, University of Sunderland, UK c The Department of Rheumatology, James Cook University Hospital, Middlesbrough, UK d The Depart…”
BackgroundInfluentialAssessing the impact of mRNA vaccination in chronic inflammatory murine model
Lee, S., Lee, J., Cho, S., Roh, G., Park, H., Lee, Y.-J., Jeon, H.-E., Lee, Y., Bae, S., Youn, S. B., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00825-z · Cited by 27
Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development
He, X., He, C., Hong, W., Yang, H. J., & Wei, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21941 · Cited by 28
“However, in Qatar, the effectiveness of the BNT162b2 vaccine was reduced by approximately 20% against the Beta variant as detected 14 days after the second dose of vaccination.(127,157) This is consistent with the speculation that the E484K mutation affects the efficacy of the BNT162b2 vaccine.”
BackgroundResultGerosa, M., Schioppo, T., Argolini, L. M., Sciascia, S., Ramirez, G. A., Moroni, G. L., Sinico, R. A., Bonelli, G. D., Alberici, F., Mescia, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10050663 · Cited by 23
Simpson, C. R., Kerr, S., Katikireddi, S. V., McCowan, C., Ritchie, L. D., Pan, J., Stock, S. J., Rudan, I., Tsang, R. S. M., de Lusignan, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32264-6 · Cited by 24
Efectividad y seguridad de las vacunas para el SARS-CoV-2 actualmente disponibles
Marco, J. J. G., Pasquín, M. J. Á., & Martín, S. M. (2021) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2021.07.001 · Cited by 25
The misunderstanding of vaccine efficacy
Tentori, K., Passerini, A., Timberlake, B., & Pighin, S. (2021) · Social Science & Medicine · doi:10.1016/j.socscimed.2021.114273 · Cited by 28
Tan, W. C., Tan, J. Y. J., Lim, J. S. J., Tan, R. S. Y. C., Lee, A. R. Y. B., Leong, F. L., Lee, S. C., Chai, L. Y. A., Tan, T. T., Malek, M. I. B. A., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2271 · Cited by 26
Inflammatory myopathy following coronavirus disease 2019 vaccination: A systematic review
Ding, Y., & Ge, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1007637 · Cited by 23
Kaura, A., Trickey, A., Shah, A. S. V., Benedetto, U., Glampson, B., Mulla, A., Mercuri, L., Gautama, S., Costelloe, C., Goodman, I., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101344 · Cited by 23
Johnson, K. W., Patel, S. A., Thapi, S., Jaladanki, S. K., RAO, A., Nirenberg, S., & Lala, A. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.05.008 · Cited by 25
“1 increased risk of severe complications, including death, of patients with heart failure (HF) who have been hospitalized due to COVID-19.(1-4) Vaccination against COVID-19 has been proven to be highly effective in preventing adverse outcomes in the general population, but concern about potential cardiovascular sequel…”
BackgroundTrigeminal and cervical radiculitis after tozinameran vaccination against COVID-19
Narasimhalu, K., Lee, W. C., Salkade, P. R., & Silva, D. A. D. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-242344 · Cited by 23
Racine‐Brzostek, S., Yee, J. K., Sukhu, A. C., Qiu, Y., Rand, S., Barone, P. D., Hao, Y., Yang, H. S., Meng, Q. H., Apple, F. S., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151477 · Cited by 25
“In addition to clinical trials conducted to determine the safety and efficacy of the mRNA 10 vaccines,(3-5) additional studies began describing the serological response to the vaccines 11 under “real-world” conditions, especially with the onset of the SARS-CoV-2 variants and case 12”
MethodBuchwinkler, L., Solagna, C. A., Messner, J., Pirklbauer, M., Rudnicki, M., Mayer, G. J., & Kerschbaum, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010148 · Cited by 31
SARS-CoV-2 Variants and Vaccination
Liu, Y., Liu, J., & Shi, P. (2022) · Zoonoses · doi:10.15212/zoonoses-2022-0001 · Cited by 23
“The Pfizer/BioNTech BNT162b2 nucle osidemodified mRNA vaccine is one of the most common vaccines, which has been widely used in North America and Europe [41].”
BackgroundStrobel, S. B., Machiraju, D., Kälber, K. A., & Hassel, J. C. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03133-w · Cited by 24
“This incidence appears to be consistent with the normal rate for this AE [10, 11].”
ResultMiyazawa, K., Liu, Y., & Bazzazi, H. (2024) · Frontiers in Nanotechnology · doi:10.3389/fnano.2024.1330406 · Cited by 26
Publication trends of research on COVID-19 and host immune response: A bibliometric analysis
Xia, Y. Q., Yao, R.-Q., Zhao, P., Tao, Z., Zheng, L., Zhou, H., Yao, Y.-M., & Song, X. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.939053 · Cited by 23
Graninger, M., Stumpf, J., Bond, G., Görzer, I., Springer, D. N., Kessel, F., Kröger, H., Frank, K., Tonn, T., Hugo, C., et al. (2023) · Journal of Clinical Virology · doi:10.1016/j.jcv.2023.105428 · Cited by 26
“To appear in: Journal of Clinical Virology Received date: 8 February 2023 Revised date: 14 March 2023 Accepted date: 19 March 2023 Please cite this article as: Marianne Graninger , Julian Stumpf , Gregor Bond , Irene Görzer , David Springer , Friederike Kessel , Hannah Kröger , Kerstin Frank , Torsten Tonn , Christian…”
BackgroundGhosh, S., & Mitra, P. (2023) · Comput. Methods Programs Biomed. · doi:10.1016/j.cmpb.2023.107955 · Cited by 23
Nanomedicine, a valuable tool for skeletal muscle disorders: Challenges, promises, and limitations
Colapicchioni, V., Millozzi, F., Parolini, O., & Palacios, D. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1777 · Cited by 29
An overview of the ongoing challenges in SARS-CoV-2 global control
Shehata, A. A., Parvin, R., Nagy, A., Wang, Y., Azhar, T. M., Attia, Y. A., Azhar, E. I., Paul, A. K., & Rahmatullah, M. (2021) · German Journal of Microbiology · doi:10.51585/gjm.2021.2.0006 · Cited by 24
Peng, L., Renauer, P. A., Ökten, A., Fang, Z., Park, J. J., Zhou, X., Lin, Q., Dong, M. B., Filler, R., Xiong, Q., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100634 · Cited by 21
González‐Parra, G., Cogollo, M. R., & Arenas, A. J. (2022) · Axioms · doi:10.3390/axioms11030109 · Cited by 23
Guzmán-Martínez, O., Guardado, K., de Guevara, E. L., Navarro, S. M., Hernández, C., Zenteno‐Cuevas, R., & Montero, H. (2021) · Vaccines · doi:10.3390/vaccines9090999 · Cited by 27
“Two groups were formed—the first comprised those vaccinated with BNT162b2, from whom a sample was taken between three and four weeks after the first dose and a second sample two to three weeks after the second dose—based on previous published studies with this vaccine [6,7,9].”
ResultPaoletti, G., Racca, F., Piona, A., Melone, G., Merigo, M., Puggioni, F., Ferri, S., Azzolini, E., Lagioia, M., Lamacchia, D., et al. (2021) · World Allergy Organization Journal · doi:10.1016/j.waojou.2021.100541 · Cited by 23
“These cases have elicited a lot of clamor, prompting the necessity to determine the real prevalence of allergic reactions to the vaccines, especially because no cases of anaphylaxis were reported in randomized clinical trials with the vaccine.(4,5)”
Chapin-Bardales, J., Myers, T., Gee, J., Shay, D. K., Marquez, P., Baggs, J., Zhang, B., Licata, C., & Shimabukuro, T. T. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.019 · Cited by 23
“Commonly reported local and systemic reactions in clinical trials of BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines included injection site pain, fatigue, and headache; these were more frequently reported after dose 2 for both vaccines [3,4].”
InfluentialUnderwood, A. P., Sølund, C. S., Fernandez-Antunez, C., Villadsen, S. L., Mikkelsen, L. S., Fahnøe, U., Bollerup, S., Winckelmann, A. A., Schneider, U. V., Binderup, A., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104475 · Cited by 23
Saki, M., Ghanbari, M. K., Behzadifar, M., Imani-Nasab, M. H., Behzadifar, M., Azari, S., Bakhtiari, A., Wu, J., & Bragazzi, N. L. (2021) · The Yale Journal of Biology and Medicine · Cited by 26
Ong, E., Huang, X., Pearce, R., Zhang, Y., & He, Y. O. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.12.039 · Cited by 25
Seroresponse to SARS-CoV-2 Vaccines Among Maintenance Dialysis Patients
Hsu, C. M., Weiner, D. E., Aweh, G. N., Manley, H. J., Ladik, V., Frament, J. M., Miskulin, D. C., Argyropoulos, C., Abreo, K. D., Chin, A. I., et al. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.10.002 · Cited by 24
Hu, Z., van der Ploeg, K., Chakraborty, S., Arunachalam, P. S., Mori, D. A., Jacobson, K. B., Bonilla, H. F., Parsonnet, J., Andrews, J. R., Holubar, M. K., et al. (2022) · eLife · doi:10.7554/elife.77943 · Cited by 33
Capuano, R., Altieri, M., Conte, M., Bisecco, A., d’Ambrosio, A., Donnarumma, G., Grimaldi, E., Coppola, N., Medici, N., Galdiero, M., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11296-4 · Cited by 23
“1 3 Indeed, even if most pwMS were able to mount similarly to their healthy peers [1, 2] an efficient [5–7] and persistent (up to six months) [8, 9] humoral response after 2 doses of mRNA COVID-19 vaccine, a relevant percentage of those treated with two HE-DMTs such as Ocrelizumab (OCR) and Fingolimod (FNG) showed a b…”
BackgroundResultInfluentialSauerwein, K. M. T., Geier, C. B., Stemberger, R. F., Akyaman, H., Illes, P., Fischer, M. B., Eibl, M. M., Walter, J. E., & Wolf, H. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.827048 · Cited by 22
“, with BNT162b2, a new COVID-19 mRNA vaccine (12, 13).”
BackgroundChambers, C., Samji, H., Cooper, C., Costiniuk, C. T., Janjua, N. Z., Kroch, A. E., Arbess, G., Benoit, A. C., Buchan, S. A., Chung, H., et al. (2022) · AIDS · doi:10.1097/qad.0000000000003405 · Cited by 22
Advances in Engineering Circular RNA Vaccines
Zhang, Z., Fu, Y., Ju, X., Zhang, F., Zhang, P., & He, M. (2024) · Pathogens · doi:10.3390/pathogens13080692 · Cited by 28
“The COVID-19 outbreak in 2019 brought great health threats to the world, and the mRNA-based COVID-19 vaccines developed by Moderna and BioNTech have achieved more than 95% effectiveness in clinical trials with minimal side effects [49,83,118].”
BackgroundSide-effects of COVID-19 vaccines among the Saudi population: A cross-sectional study
Almughais, E. S., Alharbi, A. H., Aldarwish, H. A., Alshammari, A. F., Alsuhaymi, R. S., Almuaili, J., & Alanizy, A. M. (2022) · Saudi Medical Journal · doi:10.15537/smj.2022.43.4.20210905 · Cited by 25
Doherty, J., Morain, N. O., Stack, R., Girod, P., Tosetto, M., Inzitiari, R., Sheridan, J., Cullen, G. J., McDermott, E., Buckley, M., et al. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac029 · Cited by 25
Public fear of COVID-19 vaccines in Iraqi Kurdistan region: a cross-sectional study
Tahir, A. I., Ramadhan, D. S., Taha, A. A., Abdullah, R. Y., Karim, S. K., Ahmed, A. K., & Ahmed, S. F. (2021) · Middle East Current Psychiatry · doi:10.1186/s43045-021-00126-4 · Cited by 23
“Firstly, knowledge regarding AstraZeneca’s side effects was more widely disseminated than other forms [37, 38]; second, the media and expert groups paid more attention to the mechanism of action of mRNA vaccines, resulting in a higher degree of understanding and acceptance [14].”
BackgroundCOVID-19 Vaccine: Between Myth and Truth
Piccaluga, P. P., Guardo, A. D., Lagni, A., Lotti, V., Diani, E., Navari, M., & Gibellini, D. (2022) · Vaccines · doi:10.3390/vaccines10030349 · Cited by 23
“BNT162b2 encodes a membrane-anchored, full-length SARS-CoV-2 spike protein modified by two proline mutations to stabilize the protein in its prefusion conformation [45].”
BackgroundHemmi, T., Ainai, A., Hashiguchi, T., Tobiume, M., Kanno, T., Iwata‐Yoshikawa, N., Iida, S., Sato, Y., Miyamoto, S., Ueno, A., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.049 · Cited by 25
“Typical examples include the mRNA vaccines [3,4] and the viral vector vaccines [5,6].”
Kroidl, I., Mecklenburg, I., Schneiderat, P., Müller, K., Girl, P., Wölfel, R., Sing, A., Dangel, A., Wieser, A., & Höelscher, M. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.30.2100673 · Cited by 23
“Case description The HCW in their early 60s was vaccinated with the first dose of Comirnaty in mid-January and received their second dose 21 days later, according to the recommendations at that time [3].”
BackgroundMethodInfluentialCovid-19 and radiotherapy: a systematic review after 2 years of pandemic
Piras, A., Venuti, V., D’Aviero, A., Cusumano, D., Pergolizzi, S., Daidone, A., & Boldrini, L. (2022) · Clinical and Translational Imaging · doi:10.1007/s40336-022-00513-9 · Cited by 27
“However, thanks to the effectiveness and spread of Covid19 vaccines around the world, there has been a decrease in mortality rate [5].”
BackgroundCOVID‐19 “second wave” and vaccines: the dermatologists’ perspective
Burlando, M., Russo, R. L., Cozzani, E., et al. (2021) · International Journal of Dermatology · doi:10.1111/ijd.15547 · Cited by 22
Miyara, M., Saichi, M., Sterlin, D., Anna, F., Marot, S., Mathian, A., Atif, M., Quentric, P., Mohr, A., Claër, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.790334 · Cited by 26
“Going further, our findings might be of particular relevance in understanding the the efficacy of the the recently approved SARS-CoV-2 vaccines (21), there are two published reports on large populations receiving the mRNA-based vaccines showing that protection could be achieved as early as 12 days after the first dose…”
ResultErra, L., Uriarte, I. L., Colado, A., Paolini, M. V., Seminario, G. A., Fernández, J. B., Tau, L., Bernatowiez, J., Moreira, I., Vishnopolska, S. A., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01382-7 · Cited by 24
Magro, F., Nuzzo, A., Abreu, C., Libânio, D., Rodríguez–Lago, I., Pawlak, K. M., Hollenbach, M., Brouwer, W. P., & Siau, K. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12115 · Cited by 21
“Data from Phase 3 clinical trials (BNT162b2, mRNA‐1273, and ChAdOx1 nCoV‐19), that included almost 100,000 adults, showed that mild local injection site reactions (pain, swelling, redness) and systemic features (fatigue, headache, chills) were common, but not serious, for most vaccines.(138,139,146) So far, except for…”
Backgroundvan Gils, M. J., van Willigen, H. D. G., Wynberg, E., Han, A. X., van der Straten, K., Burger, J. A., Poniman, M., Oomen, M., Tejjani, K., Bouhuijs, J. H., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100486 · Cited by 32
Development of COVID-19 vaccine policy — United States, 2020–2023
Oliver, S. E., Wallace, M. M., Twentyman, E., Moulia, D., Godfrey, M., Link‐Gelles, R., Meyer, S. A., Fleming-Dutra, K. E., Hall, E., Wolicki, J., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.12.022 · Cited by 27
“Large clinical trials were conducted, enrolling 30,000–40,000 individuals[23–25].”
Overview of approved and upcoming vaccines for SARS-CoV-2: a living review
Alderson, J., Batchelor, V., O’Hanlon, M., Cifuentes, L., Richter, F. C., & Kopycinski, J. T. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab010 · Cited by 22
Alveolar Nitric Oxide as a Biomarker of COVID-19 Lung Sequelae: A Pivotal Study
Cameli, P., Bargagli, E., Bergantini, L., d’Alessandro, M., Giugno, B., Gentili, F., & Sestini, P. (2021) · Antioxidants · doi:10.3390/antiox10091350 · Cited by 23
Kyprianidou, M., Konstantinou, P., Álvarez‐Gálvez, J., Ceccarelli, L., Gruszczyńska, E., Mierzejewska-Floreani, D., Loumba, N., Montagni, I., Tavoschi, L., Karekla, M., et al. (2022) · Behavioral Medicine · doi:10.1080/08964289.2022.2071198 · Cited by 22
“12,13 In addition, a systematic review 14 found that the global acceptance rates of COVID-19 vaccine were largely variable until December 2020 ranging from 24% in Kuwait to 97% in Ecuador, with the lowest rates observed in the Middle East, Eastern Europe and Russia and the highest in East and South…”
BackgroundSansone, E., Tiraboschi, M. M., Sala, E., Albini, E., Lombardo, M., Castelli, F., & Palma, G. D. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.04.038 · Cited by 22
Kitajima, T., Funauchi, A., Nakajima, T., Marumo, S., Imura, Y., & Fukui, M. (2022) · The Journal of Rheumatology · doi:10.3899/jrheum.220259 · Cited by 24
Nham, E., Ko, J., Song, K., Choi, J., Kim, E. S., Kim, H., Kim, B., Lim, H.-Y., Kim, K.-C., Jang, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968105 · Cited by 24
“Both vaccines were initially designed for administration in two doses at three(BNT) or four- (ChAd) week intervals (3, 4), but vaccination strategies in South Korea have been amended several times because of serious vaccine-induced adverse effects and vaccine supplements (5–8).”
BackgroundEfficacy of three COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study
Dauriat, G., Beaumont, L., Nguyen, L. B. L., Renaud-Picard, B., Penhouet, M., Coiffard, B., Salpin, M., Demant, X., Raymond, C. S., Carlier, N., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.00502-2022 · Cited by 22
“In our cohort, this proportion was only 16%, in marked contrast to the high proportions of responders in the original clinical trials in immunocompetent individuals [26, 27].”
Gazitt, T., Eviatar, T., Shear, J., Meidan, R., Furer, V., Feld, J., Haddad, A., Elias, M., Hijazi, N., Stein, N., et al. (2023) · Vaccines · doi:10.3390/vaccines11020476 · Cited by 24
Kim, J. Y., Lim, S. Y., Park, S., Kwon, J., Bae, S., Park, J. Y., Cha, H. H., Seo, M. H., Lee, H. J., Lee, N., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab579 · Cited by 22
“The lipid nanoparticleformulated mRNA-based vaccine, BNT162b2, developed by BioNTech/Pfizer has been reported to be 95% effective in preventing COVID-19 [1].”
BackgroundLiu, W., Zhang, M., Lv, H., & Yang, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17080950 · Cited by 28
“Notably, the LNP formulations used in the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccines were approved by both the U.S. FDA and the European Medicines Agency (EMA) in 2020, marking a major milestone in the field [7,8].”
Dalwadi, V., Hancock, D., Ballout, A. A., & Geraci, A. P. (2021) · Cureus · doi:10.7759/cureus.18291 · Cited by 23
“There were no reported neuroinflammatory events in the Pfizer-BioNTech phase 2/3 trial [7].”
Background(2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.08.018 · Cited by 24
Otero-Losada, M., Petrovsky, N., Alami, A., Crispo, J. A., Mattison, D., Capani, F., Goetz, C., Krewski, D., & Perez-Lloret, S. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2120607 · Cited by 22
“the mRNA-based BNT162b2 vaccine (Pfizer-BioNTech) [2];”
No apparent association between mRNA COVID-19 vaccination and venous thromboembolism
Nicholson, M. C., Goubran, H. A., Chan, N., & Siegal, D. M. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100970 · Cited by 22
“Large randomized controlled trials evaluating mRNA COVID-19 vaccines including the BNT162b2 Pfizer–BioNTech [1] and mRNA-1273 Moderna [2,3] vaccines reported similarly low rates of VTE events in both the vaccine or placebo arms but these studies were designed to assess vaccine efficacy and had limited statistical powe…”
van der Toorn, W., Oh, D., Bourquain, D. R., Michel, J., Krause, E., Nitsche, A., & von Kleist, M. (2021) · Patterns · doi:10.1016/j.patter.2021.100262 · Cited by 23
Roy, S., Ghani, K., de Campos-Lima, P. O., & Caruso, M. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198305 · Cited by 24
Cassidy, A. G., Li, L., Golan, Y., Gay, C., Lin, C. Y., Jigmeddagva, U., Chidboy, M. A., Ilala, M., Buarpung, S., Gonzalez, V. J., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.23405 · Cited by 26
Carnell, G., Billmeier, M., Vishwanath, S., Sans, M. S., Wein, H., George, C. L., Neckermann, P., Rosario, J. M. M. D., Sampson, A., Einhauser, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1118523 · Cited by 23
Knowledge about COVID-19 vaccine and vaccination in Vietnam: A population survey
Duong, M. C., Thuy, D. B., Nguyen, H. T., Quynh, T. N. T., & Nguyen, D. (2022) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2022.01.014 · Cited by 23
N2 modified dinucleotide cap analogs as a potent tool for mRNA engineering
Grzela, R., Piecyk, K., Stankiewicz-Drogoń, A., Pietrow, P., Łukaszewicz, M., Kurpiejewski, K., Darżynkiewicz, E., & Jankowska‐Anyszka, M. (2022) · RNA · doi:10.1261/rna.079460.122 · Cited by 23
Polypept(o)ides – Origins, synthesis, applications and future directions
Bauer, T. A., Simić, L., Guyse, J. F. R. V., Duro‐Castaño, A., Nebot, V. J., & Barz, M. (2024) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2024.101889 · Cited by 29
Wu, X., Li, W., Rong, H., Pan, J., Zhang, X., Hu, Q., Shi, Z., Zhang, X., & Cui, Z. (2024) · ACS Nano · doi:10.1021/acsnano.4c03075 · Cited by 24
Biosecurity risks associated with vaccine platform technologies
Sandbrink, J. B., & Koblentz, G. D. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.02.023 · Cited by 31
The Race for COVID-19 Vaccines: The Various Types and Their Strengths and Weaknesses
Muhar, B. K., Nehira, J., Malhotra, A., & Kotchoni, S. O. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900221097248 · Cited by 26
“Full immunity is assumed to be reached 7 to 10 days after the administration of the second dose.(32) Recent studies have demonstrated significant efficacy even after a single dose of the BNT162b2 vaccine, though this requires further analysis.”
BackgroundResultInfluentialModeling the Impact of COVID-19 Vaccination in Lebanon: A Call to Speed-Up Vaccine Roll Out
Mumtaz, G. R., El‐Jardali, F., Jabbour, M., Harb, A., Abu-Raddad, L. J., & Makhoul, M. (2021) · Vaccines · doi:10.3390/vaccines9070697 · Cited by 25
Efficacy of COVID-19 vaccines by race and ethnicity
Salari, N., Vepa, A., Daneshkhah, A., Darvishi, N., Ghasemi, H., Khunti, K., & Mohammadi, M. (2022) · Public Health · doi:10.1016/j.puhe.2022.04.009 · Cited by 24
Singh, V., Obregon-Perko, V., Lapp, S. A., Horner, A. M., Brooks, A. D., Macoy, L., Hussaini, L., Lu, A., Gibson, T., Silvestri, G., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155145 · Cited by 22
Addressing COVID-19 vaccine hesitancy
Kassianos, G. C., Puig‐Barberà, J., Dinse, H., Teufel, M., Türeci, Ö., & Pather, S. (2022) · Drugs in Context · doi:10.7573/dic.2021-12-3 · Cited by 24
Self-citationRe-directing nanomedicines to the spleen: A potential technology for peripheral immunomodulation
Kaur, S., Allan, S. M., & Al-Ahmady, Z. S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.005 · Cited by 25
COVID-19 Vaccination in Patients with Chronic Liver Disease
Schinas, G., Polyzou, E., Mitropetrou, F., Pazionis, A., Gogos, C. A., Triantos, C. K., & Akinosoglou, K. (2022) · Viruses · doi:10.3390/v14122778 · Cited by 23
Dynamic Interactions of Fully Glycosylated SARS-CoV-2 Spike Protein with Various Antibodies
Cao, Y., Choi, Y. K., Frank, M., Woo, H., Park, S., Yeom, M. S., Seok, C., & Im, W. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00552 · Cited by 24
Babu, T. M., Feldstein, L. R., Saydah, S., Acker, Z., Boisvert, C. L., Briggs‐Hagen, M., Carone, M., Casto, A. M., Cox, S. N., Ehmen, B., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-071446 · Cited by 26
Hirotsu, Y., Amemiya, K., Sugiura, H., Shinohara, M., Takatori, M., Mochizuki, H., & Omata, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.722766 · Cited by 22
Lazarus, R., Taucher, C., Brown, C., Ramljak, I. C., Danon, L., Dubischar, K. L., Duncan, C. J. A., Eder-Lingelbach, S., Faust, S. N., Green, C., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.06.009 · Cited by 30
Wallace, M. M., Rosenblum, H. G., Moulia, D., Broder, K. R., Shimabukuro, T. T., Taylor, C. A., Havers, F. P., Meyer, S. A., Dooling, K. L., Oliver, S. E., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.037 · Cited by 21
Lasagna, A., Bergami, F., Lilleri, D., Percivalle, E., Quaccini, M., Alessio, N., Comolli, G., Sarasini, A., Sammartino, J. C., Ferrari, A., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100458 · Cited by 20
“The BNT162b2 vaccine was the first authorized for active immunization with a 95% protection against SARS-CoV-2 infection in a phase II/III trial.(2) The efficacy of this vaccine was demonstrated as early as 11 days after the first dose in 91.”
Operational research for the safe and effective design of COVID-19 mass vaccination centres
Wood, R. M., Murch, B. J., Moss, S. J., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.024 · Cited by 22
“With news, in late 2020, that vaccination against COVID-19 may be up to 95% effective, we have entered a new chapter in our fight against the disease [1].”
BackgroundSriram, V., Conard, A. M., Rosenberg, I., Kim, D., Saponas, T. S., & Hall, A. K. (2025) · Scientific Reports · doi:10.1038/s41598-025-90453-x · Cited by 31
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.